Selective inhibition downstream of ROCK signaling, e.g., by targeting SRF/myocardin as with CCG-100602, provides a new avenue to the development of safer therapies by specifically targeting the pathological alterations of hypertension while minimizing off-target effects. The gene discussed is MYOCD; the disease is hypertensive disorder.